Rebecca Weil, PhD.

ZUG, Switzerland and BOSTON—Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company, announced the appointment of a global commercial executive with extensive ophthalmology experience, Rebecca Weil, PhD, to the role of chief commercial officer. In this role, Weil will lead the organization to commercial readiness from designing launch strategies for U.S. and globally, and building the required commercial infrastructure to bring all of Oculis’ ophthalmic product candidates to markets worldwide. Riad Sherif, MD, chief executive officer at Oculis, said, “We are thrilled to have Rebecca join us at Oculis.

"With her significant commercial leadership experience in ophthalmology spanning global strategy, marketing, and market access and her solid U.S. market knowledge, Rebecca is the perfect fit for this role especially as Oculis initiates preparation of its anticipated first U.S. launch with OCS-01. Her experience in building commercial functions from the ground up and strong track record in launching ophthalmology drugs for both retina and front-of-the-eye indications, including Xiidra in the U.S. for dry eye disease, will be instrumental to ensure commercial success with Oculis’ diversified pipeline, upon approval and expected launch," Dr. Sherif said.

Weil is a seasoned commercial executive with 20 years of experience in biotech and large pharmaceutical companies at the global, regional, and local levels. Prior to joining Oculis, she was the senior vice president, head of global marketing for Idorsia where she built the team, defined the go-to-market strategies and launched the company’s first two products.

Weil started her career in strategic consulting at McKinsey & Company, and held commercial leadership positions at Novartis, Bausch + Lomb, Alcon and Shire where she led the global ophthalmology and neuroscience franchises and product launch strategy development. She received her PhD in political science from Massachusetts Institute of Technology (MIT) and holds a BA in public and international affairs from Princeton University.

Weil added, “This is a very exciting time to join Oculis and I look forward to building a strong commercial organization and preparing Oculis for its first potential launch in the U.S. with OCS-01 for the treatment of inflammation and pain following ocular surgery. I am delighted to begin working with the team to develop the commercial strategy that will enable Oculis to reach its full potential, ensure company and market readiness to achieve commercial success and deliver its innovative therapies to patients worldwide.”